Lexaria Bioscience (LEXX) Current Assets (2011 - 2026)
Lexaria Bioscience (LEXX) posted Current Assets of $4.1 million for Q2 2026, down 29.56% sequentially from $5.8 million in Q1 2026, and down 30.0% YoY from $5.8 million in Q2 2025.
Lexaria Bioscience (LEXX) Current Assets (2011 - 2026) Analysis & Trends
Lexaria Bioscience has reported Current Assets for 16 years, with the latest figure at $4.1 million in Q2 2026.
- Quarterly Current Assets fell 30.0% year-over-year to $4.1 million in Q2 2026, while the trailing twelve-month figure through May 2026 was $4.1 million (down 30.0% YoY) and the FY2025 annual result came in at $3.5 million, down 56.09% from the prior year.
- Current Assets declined to $4.1 million in Q2 2026 per LEXX's latest filing, from $5.8 million in the prior quarter.
- Over five years, Current Assets peaked at $10.6 million in Q1 2022 and troughed at $2.2 million in Q3 2023.
- A 5-year average of $6.0 million and a median of $5.6 million in 2024 frame the typical range for Current Assets.
- The sharpest annual moves came in 2023 and 2024: Current Assets slumped 69.17% in 2023, then surged 267.14% in 2024.
- Over 5 years, Current Assets stood at $5.4 million in 2022, then tumbled by 49.74% to $2.7 million in 2023, then surged by 227.65% to $8.8 million in 2024, then tumbled by 39.23% to $5.4 million in 2025, then slipped by 24.21% to $4.1 million in 2026.
- According to Business Quant data, Current Assets over the past three periods registered $4.1 million, $5.8 million, and $5.4 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.14 Bn | 132.29 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 87.02 Bn | 79.03 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 65.30 Bn | 60.12 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 60.84 Bn | 55.70 Bn | 52.00 Mn | 5.82 Bn |
| 5 | BeOne Medicines | 42.15 Bn | 37.06 Bn | 1.53 Bn | 7.22 Bn |
| 6 | Alnylam Pharmaceuticals | 31.49 Bn | 28.18 Bn | 992.69 Mn | 4.62 Bn |
| 7 | BioNTech SE | 28.78 Bn | 10.38 Bn | 668.28 Mn | 18.80 Bn |
| 8 | Insmed | 27.55 Bn | 26.39 Bn | 358.27 Mn | 1.63 Bn |
| 9 | Royalty Pharma | 27.14 Bn | 26.31 Bn | - | 1.76 Bn |
| 10 | Lexaria Bioscience | 10.31 Mn | 6.70 Mn | - | 4.06 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| May 31, 2026 | 4.06 Mn |
| Feb 28, 2026 | 5.77 Mn |
| Nov 30, 2025 | 5.36 Mn |
| Aug 31, 2025 | 3.47 Mn |
| May 31, 2025 | 5.81 Mn |
| Feb 28, 2025 | 7.72 Mn |
| Nov 30, 2024 | 8.83 Mn |
| Aug 31, 2024 | 7.90 Mn |
| May 31, 2024 | 9.09 Mn |
| Feb 29, 2024 | 5.42 Mn |
| Nov 30, 2023 | 2.69 Mn |
| Aug 31, 2023 | 2.15 Mn |
| May 31, 2023 | 4.24 Mn |
| Feb 28, 2023 | 4.00 Mn |
| Nov 30, 2022 | 5.36 Mn |
| Aug 31, 2022 | 6.98 Mn |
| May 31, 2022 | 8.29 Mn |
| Feb 28, 2022 | 10.57 Mn |
| Nov 30, 2021 | 10.90 Mn |
| Aug 31, 2021 | 12.44 Mn |